Lower results don't faze Lunar
Lunar's fourth-quarter financial results continue to reflect flat conditions in the bone densitometry market, as the Madison, WI-based company saw revenues decline 4% during its fourth quarter. For the period (end-June), revenues were $21.3 million,
Lunar's fourth-quarter financial results continue to reflect flat conditions in the bone densitometry market, as the Madison, WI-based company saw revenues decline 4% during its fourth quarter. For the period (end-June), revenues were $21.3 million, compared with $22.2 million in the same period last year. Net income was $1.4 million, compared with $3.6 million in 1997.
The company's year-end results also were down. For the year, revenues were $79.7 million, a dip of 2% compared with $81.5 million reported in 1997. Net income was $6.9 million, compared with $14.3 million last year.
Despite the flat year, president Dr. Richard Mazess is optimistic that sales will increase during the next fiscal year, thanks to the Health Care Financing Administration's recent reimbursement policy on densitometry, including ultrasound, for postmenopausal women (SCAN 7/22/98). The company has also been training sales representatives from its primary care distributors, McKesson General Medical and Caligor, over the last two months.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
